Uniqure (QURE) stock surged almost 300% after announcing a breakthrough in Huntington’s disease, leading to a $175 million financing deal with Hercules Capital. The experimental therapy, AMT-130, showed sustained reductions in mutant huntingtin protein, a first in gene therapy for Huntington’s. Analysts raised price targets, but caution a potential pullback before buying.

Read more at Yahoo Finance: This Stock Is Tripling on a Key Gene Therapy Win. Should You Buy the 200%-Plus Surge Now?